Prisca 5.2.0.13

Date of report: 5/06/2025

Patient data				
Name	MRS. POOJA (B)		2506006805/NO	D (B)
Birthday	12/08/1998		2506006805/NO	D (B)
Age at sample date	26.8	Sample Date	4/06/	2025
Gestational age	12 + 3			
Correction factors				
Fetuses 2	IVF	no	Previous trisomy 21	no
Weight 74	diabetes	no	pregnancies	
Smoker no	Origin	Asian		
Biochemical data		Ultrasound data		
Parameter Value			Gestational age 12 + 2	
PAPP-A 5.31 mIU/m	0.96			
fb-hCG 42.5 ng/ml	0.46	Scan date		/2025
Risks at sampling date		, ,		59
Age risk			Nuchal translucency MoM 0.7 Nasal bone preser	
Biochemical T21 risk				resent
Combined trisomy 21 risk			er	
Trisomy 13/18 + NT	<1:10000	Qualification Trisomy 21	ns in measuring NT	
1:10 1:100 1:1000 1:10000 13 15 17 19 21 23 25 27 29 31 33 33 Trisomy 13/18 + NT The calculated risk for trisomy 13 translucency) is < 1:10000, which risk.	Age 8/18 (with nuchal	The calculated risk for Trisomy 21 (with nuchal translucency) is below the cut off, which indicates a low risk. After the result of the Trisomy 21 test (with NT) it is expected that among more than 10000 women with the same data, there is one woman with a trisomy 21 pregnancy. The risk for this twin pregnancy has been calculated for a singleton pregnancy with corrected MoMs. The calculated risk by PRISCA depends on the accuracy of the information provided by the referring physician. Please note that risk calculations are statistical approaches and have no diagnostic value! The patient combined risk presumes the NT measurement was done according to accepted guidelines (Prenat Diagn 18: 511-523 (1998)). The laboratory can not be hold responsible for their impact on the risk assessment! Calculated risks have no diagnostic value!		or a acy . ement Diagn

Sign of Physician